Related Experiment Video

Updated: Jun 20, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Haplotypes and 5A/6A polymorphism of the matrix metalloproteinase-3 gene in coronary disease: case-control study and

Werner Koch1, Antoinette de Waha, Petra Hoppmann

  • 1Deutsches Herzzentrum München and 1. Medizinische Klinik, Klinikum rechts der Isar, Technische Universität München, Lazarettstrasse 36, Munich, Germany. wkoch@dhm.mhn.de

Atherosclerosis
|September 19, 2009
PubMed
Abstract

Insights

Matrix metalloproteinase-3 (MMP3) gene variations were not linked to myocardial infarction (MI) in a German study. However, the 5A/6A polymorphism (rs3025058) showed varied risks for coronary disease in Europeans versus East Asians.

Area of Science:

  • Genetics and Cardiovascular Disease Research

Background:

  • Matrix metalloproteinase-3 (MMP3) and its gene are implicated in atherosclerotic diseases.
  • Common variations in MMP3 may influence susceptibility to myocardial infarction (MI).

Purpose of the Study:

  • To investigate the role of common MMP3 variations in MI through haplotype analysis.
  • To conduct a meta-analysis on the association between the MMP3 5A/6A polymorphism (rs3025058) and coronary diseases.

Main Methods:

  • Haplotype analysis of MMP3 single nucleotide polymorphisms in a German MI case-control study (3657 cases, 1211 controls).
  • Meta-analysis of 15 studies (10,061 cases, 8048 controls) examining the rs3025058 polymorphism and coronary disease risk.

Main Results:

  • No significant differences in genotype or haplotype frequencies of MMP3 were found between MI patients and controls.
  • The meta-analysis showed no overall association between rs3025058 (5A/6A polymorphism) and coronary disease risk (OR, 1.00; 95% CI, 0.85-1.19).
  • Trends indicated a reduced risk for 5A allele carriers of European ancestry and an increased risk for those from East Asia.

Conclusions:

  • Individual MMP3 polymorphisms and haplotypes are not associated with MI in the studied German population.
  • The rs3025058 polymorphism may have differential effects on coronary disease risk across ethnic groups, specifically between Europeans and East Asians.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...